Development of novel nucleic acid therapy for brain tumor stem cells using inactivated viral particle

• Project/Area Number: 15K19948
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Neurosurgery
• Research Institution: University of Tsukuba
• Principal Investigator: MATSUDA MASAHIDE 筑波大学, 医学医療系, 講師 (30614333)
• Research Collaborator: SUGII NARUSHI 筑波大学, 人間総合科学研究科・疾患制御医学専攻
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000); Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: 不活化ウイルス粒子 / microRNA / 脳腫瘍幹細胞 / 核酸医薬療法

Outline of Final Research Achievements

Hemagglutinating virus of Japan envelope (HVJ-E) derived from inactivated replication-defective Sendai virus was originally developed as a versatile drug delivery system. We have shown the ability of HVJ-E to highly introduce oligonucleotide as a therapeutic molecule into glioma stem-like cells. In the present study, we have shown that introduction of stemness inhibitory microRNAs such as miR-218 or miR-34a using HVJ-E vector may become a novel nucleic acid therapy for malignant gliomas.